| Code | 47416 | ||||||||||
| MA number | 21/0027/08-S | ||||||||||
| Product Form: | cps dur 200(2x100)x300 mg (blis.PVC/Al) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | Wörwag Pharma GmbH & Co. KG, Germany | ||||||||||
| Therapeutic Class: | 21 - ANTIEPILEPTICA, ANTICONVULSIVA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 13.02.2008 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| PIL: |
PIL_Gabagamma 100 300 400 cps dur_04.2023.pdf
|
| SPC: |
SPC_Gabagamma 100 300 400 cps dur_04.2023.pdf
|
| Safety feature | Yes |
| Data update: | 24.10.2018 |
